- TRADE NAME: Fruzaola (Takeda)
- INDICATIONS:
Indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
- CLASS: Kinase inhibitor
- HALF-LIFE: Mean (SD) elimination half-life is ~ 42 (11) hours.
- FDA APPROVAL DATE: 11/08/2023
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 01/12/2026
